Clinical trials: Type 2 DM
Diabetes Mellitus, Type 2
Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day
Primary Objective: To evaluate the effect of prandial treatment adjustment, based on continuous blood glucose monitoring, on glucose control in type 2 diabetes patients who are not controlled by treatment with once daily basal…
- Trial name
- SeLan (NCT01234597)
- Testing
- INSULIN GLARGINE (HOE901), INSULIN GLULISINE (HMR1964)
- Where
- 11 sites in Israel
- Volunteers
- 219 people
- Sponsor
- Sanofi
Hypercholesterolaemia
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
Primary Objectives: To demonstrate the superiority of alirocumab in comparison with placebo in the reduction of calculated low-density lipoprotein cholesterol (LDL-C) in participants with diabetes treated with insulin and with…
- Trial name
- NCT02585778
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
- Where
- 110 sites in United States, Austria and 8 more
- Volunteers
- 517 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Diabetes Mellitus Type 2 Basal Insulin Dosing Requirements Study
The main purpose of this study is to determine the number of daily basal insulin rate changes that are needed to achieve short-term near normal glucose control in insulin pump patients with type 2 diabetes
- Trial name
- NCT00874809
- Testing
- CGMS with an insulin pump using rapid acting insulin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Diabetes Care Center
Type2diabetes
DM Treatment to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone in Patients with Type 2 Diabetes
Key finding of DM Treatment with combination, A MuLticenter, Randomized, Parallel, Gathering Information of phase 4 Trial to Evaluate the Efficacy and Safety of Dapagliflozin or Pioglitazone add-on to Metformin and DPP-4…
- Trial name
- KLIMT (NCT06875193)
- Testing
- DW6012(Dasidiem tab. 10/100mg)
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Prediabetic
Efficacy and Safety of DLBS3233 in Prediabetic Patients
This is a 2-arm, prospective, double blind, randomized, and controlled clinical study for 12 weeks of therapy to investigate clinical efficacy and safety of DLBS3233.
- Trial name
- DIPPER-DM (NCT01531933)
- Testing
- DLBS3233
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Dexa Medica Group
Type 2 Diabetes Mellitus (T2DM)
Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients
The purpose of this study was to assess the efficacy and safety of vildagliptin 50 mg bid add-on therapy to improve overall glycemic control in patients with T2DM inadequately controlled by insulin, with or without concomitant…
- Trial name
- NCT02002221
- Testing
- Vildagliptin (LAF237), Insulin, Metformin
- Where
- 31 sites in Japan
- Volunteers
- 156 people
- Sponsor
- Novartis Pharmaceuticals
Type 2 Diabetes Mellitus, Liver Dysfunction
Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10mg(Mitiglinide)
This clinical trial is designed to assess the effect of hepatic impairment on the pharmacokinetic and pharmacodynamic of glufast tablets 10 mg.
- Trial name
- NCT04349696
- Testing
- Mitiglinide
- Where
- 2 sites in Taiwan
- Volunteers
- 16 people
- Sponsor
- Orient Europharma Co., Ltd.
Type 2 Diabetes
Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)
The purpose of this investigation is to describe general safety profile of type II Diabetes Mellitus (DM) Japanese patients under exenatide therapy in real world medical practices
- Trial name
- NCT01817569
- Where
- 46 sites in Japan
- Volunteers
- 2,948 people
- Sponsor
- AstraZeneca